DOBUTAMINE HYDROCHLORIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE (DOBUTAMINE HYDROCHLORIDE).
Dobutamine directly stimulates β1-adrenergic receptors in the heart, increasing myocardial contractility and stroke volume with minimal chronotropic effect at therapeutic doses. It also has mild β2 and α1 activity.
| Metabolism | Hepatic metabolism via catechol-O-methyltransferase (COMT) and conjugation; metabolites inactive. |
| Excretion | Primarily renal (90-95% as inactive metabolites, mainly glucuronide conjugates and 3-O-methyl metabolites). Less than 5% excreted unchanged. Biliary/fecal elimination is minimal (<5% in feces). |
| Half-life | 2-3 minutes (short distribution half-life). Terminal elimination half-life is approximately 2 minutes. Clinical context: Requires continuous intravenous infusion for sustained effect due to rapid clearance. |
| Protein binding | 25% (bound primarily to albumin). |
| Volume of Distribution | 0.2 L/kg (total body water). Clinical meaning: Low Vd indicates limited extravascular distribution, primarily in plasma and interstitial fluid. |
| Bioavailability | Intravenous: 100% (only parenteral route). Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism; not administered orally. |
| Onset of Action | Intravenous: 1-2 minutes (following bolus or start of infusion). |
| Duration of Action | Intravenous: 10-20 minutes after discontinuation of infusion. Clinical note: Effects diminish rapidly due to short half-life; titrate infusion rate for desired hemodynamic response. |
Intravenous infusion: 2.5-20 mcg/kg/min, titrated to hemodynamic response. Typical starting dose 2.5-5 mcg/kg/min.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for renal impairment; primarily hepatically metabolized and renally excreted unchanged fraction minimal. |
| Liver impairment | No formal Child-Pugh based guidelines; use with caution in severe hepatic impairment due to potential for reduced clearance. Monitor hemodynamics closely. |
| Pediatric use | Intravenous infusion: 2.5-20 mcg/kg/min; initiate at 2.5-5 mcg/kg/min and titrate. Limited data in neonates. |
| Geriatric use | Start at lower end of dosing range (2.5-5 mcg/kg/min) due to increased sensitivity and higher prevalence of cardiovascular comorbidities; monitor heart rate and blood pressure closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DOBUTAMINE HYDROCHLORIDE (DOBUTAMINE HYDROCHLORIDE).
| Breastfeeding | Unknown excretion into human milk; M/P ratio not available. Caution advised due to lack of data. Use only if clearly needed. |
| Teratogenic Risk | Pregnancy Category B. Animal studies have not revealed evidence of teratogenicity. No well-controlled studies in pregnant women; use only if clearly needed. In first trimester, risk is minimal but theoretical. In second and third trimesters, use for maternal hemodynamic support only if benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None
| Serious Effects |
["Idiopathic hypertrophic subaortic stenosis (IHSS)","Hypersensitivity to dobutamine or sulfites (contains sodium bisulfite)"]
| Precautions | ["May increase heart rate and exacerbate myocardial ischemia or arrhythmias","Hypovolemia should be corrected before administration","Tachyphylaxis may occur with prolonged use","Extravasation risk: central line preferred if possible","Monitoring required: ECG, blood pressure, cardiac output, pulmonary capillary wedge pressure, heart rate"] |
Loading safety data…
| Continuous ECG, blood pressure, heart rate, and oxygen saturation. Monitor infusion rate, urine output, and signs of extravasation. Fetal heart rate monitoring during use in pregnancy. |
| Fertility Effects | No adverse effects on fertility reported in animal studies. Human data lacking. |